No price history available.

Based on consensus from external analysts. Not Kvantra's opinion.

Basilea Pharmaceutica AG operates as a commercial-stage biopharmaceutical enterprise, concentrating its efforts on inventing and advancing treatments to address critical unmet medical needs within the therapeutic fields of oncology and anti-infectives. Its commercialized offerings include Cresemba, an azole antifungal drug available in both intravenous and oral formulations, utilized for managing invasive aspergillosis and mucormycosis in the United States and the European Union; this drug is also advancing through Phase III clinical trials in Japan for various invasive fungal infections. The company additionally provides Zevtera, an antibiotic targeting community and hospital-acquired pneumonia, which is also undergoing Phase III clinical development for acute bacterial skin and skin structure infections, along with Staphylococcus aureus bacteremia. Beyond its current portfolio, Basilea's pipeline features Derazantinib, a small molecule inhibitor in Phase 2 clinical trials for bile duct cancer, and in Phase 1/2 trials for both bladder and stomach cancers, as well as Lisavanbulin, a novel tumor checkpoint controller drug. Established in 2000, Basilea Pharmaceutica AG maintains its corporate headquarters in Basel, Switzerland.

• Novogene Co., Ltd.
• Hangzhou Biotest Biotech Co.,Ltd.
• Beijing Konruns Pharmaceutical Co.,Ltd.
• PeptiDream Inc.
• CHO Pharma, Inc.
• Monopar Therapeutics Inc.
• Aura Biosciences, Inc.
• Hunan Jiudian Pharmaceutical Co., Ltd.